当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
Zosyn for injection
通用名称
piperacillin/tazobactam
儿科标签批准日期
2021/7/29 0:00:00
特定指示/秒
Nosocomial pneumonia in pediatric patients 2 months and older
标签更改摘要
- Use in pediatric patients 2 months of age and older with nosocomial pneumonia is supported by evidence from well-controlled studies in adults with nosocomial pneumonia, a simulation study performed with a population pharmacokinetic model, and a retrospective, cohort study of pediatric patients with nosocomial pneumonia in which 140 pediatric patients were treated with ZOSYN and 267 patients treated with comparators (which included ticarcillin-clavulanate, carbapenems, ceftazidime, cefepime, or ciprofloxacin)
- Because of the limitations of the available strengths and administration requirements (i.e., administration of fractional doses is not recommended) of ZOSYN Injection supplied in GALAXY Containers, and to avoid unintentional overdose, this product is not recommended for use if a dose of ZOSYN Injection in GALAXY Containers that does not equal 2.25 g, 3.375 g, or 4.5 g is required and an alternative formulation of ZOSYN should be considered.
- Safety and effectiveness have not been established in pediatric patients less than 2 months.
- Information on dosing, PK parameters, adverse reactions, and clinical trials.
- Postmarketing study.